Sanofi has appointed Bill Sibold executive vice president of Sanofi Genzyme and member of the executive committee – effective July 1, 2017. Sibold succeeds David Meeker, who will leave the company at the end of June after 23 years of working at Genzyme and Sanofi. Sibold joined Sanofi in 2011 as head of the MS franchise and currently is head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization.
Meeker will be joining Rhythm’s board of directors as chair. Rhythm is a biopharma company developing peptide therapeutics for rare...




